A phase 2 trial of bevacizumab and high-dose interferon alpha 2b in metastatic melanoma

Journal of Immunotherapy

Volumn 34, Issue 6, 2011, Pages 509-515

  Grignol, Valerie P ^a   Olencki, Thomas ^b   Relekar, Kiran ^a   Taylor, Cynthia ^c   Kibler, Amanda ^c   Kefauver, Cheryl ^c   Wei, Lai ^a   Walker, Michael J ^a   Chen, Helen X ^d   Kendra, Kari ^b   Carson, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Division of Hematology and Oncology   (United States)

^c Clinical Trial Office   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

angiogenesis; bevacizumab; interferon alpha 2b; metastatic melanoma; phase 2 clinical trial; vascular endothelial growth factor

Indexed keywords

ALPHA2B INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DACARBAZINE; FIBROBLAST GROWTH FACTOR; FOTEMUSTINE; INTERLEUKIN 2; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE; VASCULOTROPIN; VINBLASTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BLEEDING; BONE METASTASIS; BRAIN HEMORRHAGE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DESQUAMATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; EMBOLISM; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEADACHE; HEART INFARCTION; HEARTBURN; HEMATURIA; HEMIPARESIS; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; KIDNEY METASTASIS; LIVER METASTASIS; LOW DRUG DOSE; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SOFT TISSUE METASTASIS; STOMATITIS; STROKE; SUBDURAL HEMATOMA; TASTE DISORDER; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT RESPONSE; TUMOR REGRESSION; VISCERAL METASTASIS; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959788909     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31821dcefd     Document Type: Article

References (35)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
2. Einspahr JG, Thomas TL, Saboda K, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer. 2007;110:2519-2527. (Pubitemid 350174939)
3. Marcoval J, Moreno A, Graells J, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol. 1997;24:212-218. (Pubitemid 27187016)
4. Simonetti O, Lucarini G, Brancorsini D, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer. 2002;95:1963-70. (Pubitemid 35222177)
5. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27: 1432-1439.
6. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227-1234.
7. Robertson JD, Botwood NA, Rothenberg ML, et al. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer. 2009;8:59-60.
8. Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009; 115:119-127.
9. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998;58:808-814. (Pubitemid 28099496)
10. Singh RK, Gutman M, Bucana CD, et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995;92:4562-4566.
11. Kirkwood JM,Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677. (Pubitemid 38435557)
12. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992; 326:1456-1463.
13. Raig ET, Jones NB, Varker KA, et al. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res. 2008;28:553-561.
14. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111. (Pubitemid 350296300)
15. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422-5428.
16. Gorski DH, Leal AD, Goydos JS. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg. 2003;197: 408-418. (Pubitemid 38373300)
17. Ugurel S, Rappl G, Tilgen W, et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19:577-583. (Pubitemid 32112873)
18. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65: 671-680. (Pubitemid 40216420)
19. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987-989. (Pubitemid 32937367)
20. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007;13:2422-2428. (Pubitemid 46698593)
21. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465-477.
22. Avastin. http://www.avastin.com/avastin/hcp/index.m. (Accessed on February 12, 2010).
23. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol. 1997;24(1 suppl 4):S24-S31.
24. Dummer R, Garbe C, Thompson JA, et al. Randomized doseescalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol. 2006;24:1188-1194. (Pubitemid 46638817)
25. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007;14:2367-2376. (Pubitemid 47174913)
26. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103. (Pubitemid 26338628)
27. Gonzalez-Cao M, Viteri S, Diaz-Lagares A, et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology. 2008;74:12-16. (Pubitemid 351915004)
28. Vihinen PP, Hernberg M, Vuoristo MS, et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon- alpha2a as first line treatment in metastatic melanoma. Melanoma Res. 2010;20:318-325.
29. O'Day SJ, Kim KB, Sosman JA, et al. 23LBA BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma. Eur J Cancer. 2009;7(suppl):13.
30. Del Vecchio M, Mortarini R, Canova S, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res. 2010. [Epub October 28].
31. Dummer R, Michielin O, Seifert B, et al. First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): a multicenter phase II trial (SAKK 50/07). J Clin Oncol (Meeting Abstracts). 2010;28(7-suppl):8521.
32. di Pietro A, Ferrucci P, Munzone E, et al. Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTh)-na?̈ve advanced melanoma (MM) patients (pts): a phase II study. J Clin Oncol (Meeting Abstracts). 2010;28(7-suppl): 8536-8853.
33. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26:3709-3714.
34. Hainsworth JD, Infante JR, Spigel DR, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010; 116:4122-4129.
35. Wyman K, Spigel D, Puzanov I, et al. A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. J Clin Oncol (Meeting Abstracts). 2007; 25(18-suppl):8539.